- Home
- BANL vs BOLT Comparison
BANL vs BOLT Comparison
Compare BANL & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANL | BOLT |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 10.5M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BANL | BOLT |
|---|---|---|
| Price | $0.34 | $7.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 40.2K | 21.3K |
| Earning Date | 09-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $580,456,800.00 | $5,195,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.38 | N/A |
| 52 Week Low | $0.30 | $4.41 |
| 52 Week High | $1.30 | $10.50 |
Technical Indicators
Market Signals| Indicator | BANL | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 31.32 | 66.28 |
| Support Level | $0.32 | $6.14 |
| Resistance Level | $0.44 | $6.60 |
| Average True Range (ATR) | 0.04 | 0.42 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 29.86 | 88.06 |
Price Performance
Historical ComparisonAbout BANL CBL International Limited
CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.